Small bowel adenocarcinoma (SBA) is a rare tumor with an unfavorable prognosis, and due to its rarity, few studies on its treatment are available. Chemotherapy remains the standard of treatment in advanced disease. Recently immunotherapy has demonstrated to be a valid therapeutic option for many solid tumors. We reviewed the data published in literature to understand the impact of immunotherapy in this cancer.
Immunotherapy in small bowel adenocarcinoma: a potential role? / Vitiello, F.; Cereda, S.; Foti, S.; Liscia, N.; Mazza, E.; Ronzoni, M.; Cascinu, S.. - In: IMMUNOLOGICAL MEDICINE. - ISSN 2578-5826. - 47:1(2024), pp. 1-5. [10.1080/25785826.2023.2220938]
Immunotherapy in small bowel adenocarcinoma: a potential role?
Vitiello F.;Mazza E.;Cascinu S.
2024-01-01
Abstract
Small bowel adenocarcinoma (SBA) is a rare tumor with an unfavorable prognosis, and due to its rarity, few studies on its treatment are available. Chemotherapy remains the standard of treatment in advanced disease. Recently immunotherapy has demonstrated to be a valid therapeutic option for many solid tumors. We reviewed the data published in literature to understand the impact of immunotherapy in this cancer.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
